RU2017112088A - Лечение неопластических заболеваний - Google Patents
Лечение неопластических заболеваний Download PDFInfo
- Publication number
- RU2017112088A RU2017112088A RU2017112088A RU2017112088A RU2017112088A RU 2017112088 A RU2017112088 A RU 2017112088A RU 2017112088 A RU2017112088 A RU 2017112088A RU 2017112088 A RU2017112088 A RU 2017112088A RU 2017112088 A RU2017112088 A RU 2017112088A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- pharmaceutical composition
- progressive
- human patient
- metastatic
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 3
- 230000001613 neoplastic effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 8
- 230000000750 progressive effect Effects 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000003937 drug carrier Substances 0.000 claims 3
- 230000001394 metastastic effect Effects 0.000 claims 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims 3
- 206010052358 Colorectal cancer metastatic Diseases 0.000 claims 2
- 239000003124 biologic agent Substances 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 230000000087 stabilizing effect Effects 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 206010003445 Ascites Diseases 0.000 claims 1
- 208000008454 Hyperhidrosis Diseases 0.000 claims 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims 1
- 230000035900 sweating Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (9)
1. Способ стабилизирования прогрессирующего рака у пациента-человека, имеющего рак, прогрессировавший после лечения посредством химиотерапии, лучевой терапии или биологическими средствами, где указанный способ включает стадию повторяемого введения субъекту фармацевтической композиции, включающей фармацевтически приемлемый носитель и антитело к IL-1α, по меньшей мере до тех пор, пока прогрессирование рака не стабилизируется.
2. Способ по п. 1, где прогрессирующий рак у пациента-человека является метастатическим, и стадия повторяемого введения указанной фармацевтической композиции приводит к снижению опухолевой нагрузки у пациента.
3. Способ по п. 1, где прогрессирующий рак представляет собой метастатический колоректальный рак.
4. Способ по п. 2, где прогрессирующий рак представляет собой метастатический колоректальный рак.
5. Способ по п. 1, где прогрессирующий рак представляет собой метастатический немелкоклеточный рак легких.
6. Способ по п. 2, где прогрессирующий рак представляет собой метастатический немелкоклеточный рак легких.
7. Способ уменьшения размера опухоли у пациента-человека с назофарингеальной карциномой, которую ранее лечили посредством химиотерапии, лучевой терапии или биологическими средствами, где указанный способ включает стадию повторяемого введения субъекту фармацевтической композиции, включающей фармацевтически приемлемый носитель и антитело к IL-1α, по меньшей мере до тех пор, пока размер опухоли не уменьшится.
8. Способ по п. 7, где пациент имеет по меньшей мере один симптом, выбранный из группы, состоящей из слабости, лихорадки, потливости и асцита, и стадия повторяемого введения указанной фармацевтической композиции приводит к уменьшению указанного по меньшей мере одного симптома.
9. Способ стабилизирования болезни Кастельмана у пациента-человека, где указанный способ включает стадию повторяемого введения субъекту фармацевтической композиции, включающей фармацевтически приемлемый носитель и антитело к IL-1α, по меньшей мере до тех пор, пока прогрессирование болезни Кастельмана не стабилизируется.
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37609710P | 2010-08-23 | 2010-08-23 | |
| US61/376,097 | 2010-08-23 | ||
| US40675910P | 2010-10-26 | 2010-10-26 | |
| US61/406,759 | 2010-10-26 | ||
| US61/408,635 | 2010-10-31 | ||
| US41118310P | 2010-11-08 | 2010-11-08 | |
| US61/411,183 | 2010-11-08 | ||
| US201161480635P | 2011-04-29 | 2011-04-29 | |
| US61/480,635 | 2011-04-29 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013110030/15A Division RU2013110030A (ru) | 2010-08-23 | 2011-08-23 | Лечение неопластических заболеваний |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017112088A true RU2017112088A (ru) | 2019-01-24 |
| RU2017112088A3 RU2017112088A3 (ru) | 2019-01-24 |
| RU2679119C2 RU2679119C2 (ru) | 2019-02-06 |
Family
ID=45594256
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013110030/15A RU2013110030A (ru) | 2010-08-23 | 2011-08-23 | Лечение неопластических заболеваний |
| RU2017112088A RU2679119C2 (ru) | 2010-08-23 | 2011-08-23 | Лечение неопластических заболеваний |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013110030/15A RU2013110030A (ru) | 2010-08-23 | 2011-08-23 | Лечение неопластических заболеваний |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10294296B2 (ru) |
| EP (3) | EP2608808B1 (ru) |
| JP (5) | JP6241932B2 (ru) |
| KR (7) | KR101910760B1 (ru) |
| CN (3) | CN103153340A (ru) |
| AU (1) | AU2011293554B9 (ru) |
| DK (1) | DK2608808T3 (ru) |
| ES (2) | ES2856723T3 (ru) |
| IL (2) | IL262856B (ru) |
| MX (2) | MX388939B (ru) |
| NZ (1) | NZ607472A (ru) |
| PH (2) | PH12013500316A1 (ru) |
| PT (1) | PT2608808T (ru) |
| RU (2) | RU2013110030A (ru) |
| SG (1) | SG187853A1 (ru) |
| WO (1) | WO2012027324A2 (ru) |
| ZA (1) | ZA201301420B (ru) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011159976A2 (en) | 2010-06-18 | 2011-12-22 | Xbiotech, Inc. | Arthritis treatment |
| CN103153340A (zh) | 2010-08-23 | 2013-06-12 | 埃克斯生物科技公司 | 对肿瘤疾病的治疗 |
| US9724409B2 (en) | 2011-04-01 | 2017-08-08 | Xbiotech, Inc. | Treatment of inflammatory skin disease |
| ES2695102T3 (es) | 2011-09-23 | 2019-01-02 | Xbiotech Inc | Tratamiento para la caquexia |
| US9545441B2 (en) | 2012-09-18 | 2017-01-17 | Xbiotech, Inc. | Treatment of diabetes |
| US20170260285A1 (en) * | 2014-11-24 | 2017-09-14 | University Of Iowa Research Foundation | Methods for treating cancer |
| CN110382001A (zh) | 2017-02-16 | 2019-10-25 | 埃克斯生物科技公司 | 化脓性汗腺炎的治疗 |
| US10975146B2 (en) | 2018-06-29 | 2021-04-13 | Cedars-Sinai Medical Center | Interleukin-1 inhibition for combination treatment of pancreatic cancer |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
| US5672347A (en) | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4965198A (en) | 1985-12-24 | 1990-10-23 | Konica Corporation | Monoclonal antibody and method of manufacturing hybridoma producing the same |
| DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
| DK590387A (da) | 1986-11-13 | 1988-05-14 | Otsuka Pharma Co Ltd | Antistoffer mod interleukin-1 |
| US5034316A (en) | 1987-03-30 | 1991-07-23 | The Regents Of The University Of California | In vitro human monoclonal IgG rheumatoid factor autoantibody |
| US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| FR2640146B1 (fr) | 1988-12-08 | 1993-12-24 | Commissariat A Energie Atomique | Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| JPH04504253A (ja) | 1989-03-27 | 1992-07-30 | セントカー・インコーポレーテツド | ＩｇＭ抗体の安定化のための配合物 |
| US5407431A (en) | 1989-07-11 | 1995-04-18 | Med-Design Inc. | Intravenous catheter insertion device with retractable needle |
| US7192584B2 (en) | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
| GB9122820D0 (en) | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
| WO1994008624A2 (en) | 1992-10-14 | 1994-04-28 | Sterling Winthrop Inc. | Therapeutic and diagnostic imaging compositions and methods |
| ATE204299T1 (de) | 1993-03-05 | 2001-09-15 | Bayer Ag | Humane monoklonale anti-tnf alpha antikörper |
| EP0659766A1 (en) | 1993-11-23 | 1995-06-28 | Schering-Plough | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
| US5959085A (en) * | 1993-11-23 | 1999-09-28 | Schering Corporation | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
| GB9405021D0 (en) | 1994-03-15 | 1994-04-27 | Unilever Plc | Skin treatment composition |
| GB9509620D0 (en) | 1995-05-12 | 1995-07-05 | Nat Blood Authority | Transepithelial transport of molecular species |
| WO1997002479A2 (en) | 1995-06-30 | 1997-01-23 | Yale University | Human monoclonal anti-tumor antibodies |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| US6962702B2 (en) | 1998-06-22 | 2005-11-08 | Immunomedics Inc. | Production and use of novel peptide-based agents for use with bi-specific antibodies |
| SE9802402D0 (sv) | 1998-07-03 | 1998-07-03 | Karolinska Innovations Ab | Method of diagnosing cardiovascular disease and early atherosclerosis |
| US20030040617A9 (en) | 1999-03-12 | 2003-02-27 | Rosen Craig A. | Nucleic acids, proteins and antibodies |
| ATE316982T1 (de) * | 1999-08-09 | 2006-02-15 | Lexigen Pharm Corp | Mehrere zytokin-antikörper komplexen |
| DE19943790C2 (de) | 1999-09-13 | 2001-11-15 | Ericsson Telefon Ab L M | Verfahren und Vorrichtung zur Bestimmung eines Synchronisationsfehlers in einem Netzwerkknoten |
| US6380129B1 (en) | 1999-11-02 | 2002-04-30 | Richard J. Kraemer | Enhanced materials for treatment of contamination |
| US6811788B2 (en) | 2000-01-19 | 2004-11-02 | Baofa Yu | Combinations and methods for treating neoplasms |
| US20030232054A1 (en) | 2000-01-25 | 2003-12-18 | Tang Y. Tom | Novel nucleic acids and polypeptides |
| US20020131954A1 (en) | 2000-05-02 | 2002-09-19 | Tobinick Edward L. | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
| AU2007202323C1 (en) | 2000-06-29 | 2012-04-12 | Abbvie Inc. | Dual specificity antibodies and methods of making and using |
| US20040086507A1 (en) | 2000-10-19 | 2004-05-06 | Kenya Shitara | Antibody inhibiting vplf activity |
| US20030026806A1 (en) * | 2000-10-27 | 2003-02-06 | Amgen Inc. | Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof |
| US7348003B2 (en) * | 2001-05-25 | 2008-03-25 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors |
| AU2002343609B2 (en) | 2001-11-16 | 2008-12-11 | Als Therapy Development Foundation, Inc. | Treatment of neurodegenerative disorders through the modulation of the polyamine pathway |
| EP2295468B1 (en) | 2002-02-14 | 2015-07-08 | Immunomedics, Inc. | Anti-CD20 antibodies and fusion proteins thereof and methods of use |
| DE60325184D1 (de) | 2002-03-01 | 2009-01-22 | Immunomedics Inc | Rs7 antikörper |
| NZ566539A (en) | 2002-09-06 | 2010-01-29 | Medarex Inc | Therapeutic human anti-IL-1R1 monoclonal antibody |
| JP4450644B2 (ja) | 2003-03-03 | 2010-04-14 | 日本化薬株式会社 | Ａｍｆ類を有効成分とする医薬製剤 |
| US20040224893A1 (en) | 2003-05-06 | 2004-11-11 | Li-Hsien Wang | Methods of using IL-1 antagonists to treat neointimal hyperplasia |
| NZ544486A (en) | 2003-06-13 | 2009-04-30 | Biogen Idec Inc | Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof |
| KR100493102B1 (ko) | 2003-06-30 | 2005-06-02 | 삼성전자주식회사 | 서브 하우징 스토퍼를 구비하는 휴대용 단말기의 힌지 장치 |
| HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| US7799327B2 (en) | 2003-12-24 | 2010-09-21 | Henry John Smith | Autoantibodies utilized as carrier agents for pharmaceutical compounds used in cancer treatment |
| US7105183B2 (en) | 2004-02-03 | 2006-09-12 | The Regents Of The University Of California | Chlorite in the treatment of neurodegenerative disease |
| US8957056B2 (en) | 2004-05-25 | 2015-02-17 | Sloan-Kettering Instiute For Cancer Research | Migrastatin analogs in the treatment of cancer |
| US20050276807A1 (en) | 2004-06-15 | 2005-12-15 | Advanced Biotherapy, Inc. | Treatment of acne |
| WO2006036936A2 (en) | 2004-09-27 | 2006-04-06 | Bridge Pharma, Inc. | The s-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents |
| AU2005314392B2 (en) * | 2004-12-09 | 2011-04-14 | Centocor, Inc. | Anti-integrin immunoconjugates, methods and uses |
| DE602006014691D1 (de) | 2005-08-02 | 2010-07-15 | Xbiotech Inc | DIAGNOSE, BEHANDLUNG UND PRÄVENTION VON GEFÄSSERKRANKUNGEN MITTELS IL-1alpha-AUTOANTIKÖRPERN |
| US20090215992A1 (en) | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP1931383A1 (en) | 2005-09-28 | 2008-06-18 | Cytos Biotechnology AG | Interleukin-1 conjugates and uses thereof |
| EP2021026A1 (en) | 2006-04-14 | 2009-02-11 | Novartis AG | Use of il-i antibodies for treating ophthalmic disorders |
| US20110008282A1 (en) | 2006-05-15 | 2011-01-13 | Xbiotech, Inc. | IL-1alpha immunization induces autoantibodies protective against atherosclerosis |
| ES2384278T3 (es) | 2006-05-15 | 2012-07-03 | Xbiotech, Inc | IL-1-alfa para su uso en un procedimiento de tratamiento de placas ateroscleróticas |
| DK2109623T3 (da) * | 2006-05-22 | 2012-01-30 | Xbiotech Inc | Cancerbehandling med anti-IL-1-antistoffer |
| HRP20140172T1 (hr) | 2006-05-30 | 2014-03-28 | Genentech, Inc. | Protutijela i imunokonjugati kao i njihove uporabe |
| FR2902659A1 (fr) | 2006-06-23 | 2007-12-28 | Pierre Fabre Medicament Sa | Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires |
| EP2114443A4 (en) | 2006-12-29 | 2011-08-10 | Abbott Lab | IL-1A / IL-1B ANTIBODY WITH DOUBLE SPECIFICITY |
| CN102056485A (zh) | 2008-04-15 | 2011-05-11 | 萨可德公司 | 用于局部治疗免疫相关疾病的局部lfa-1拮抗剂 |
| US8034337B2 (en) | 2008-05-30 | 2011-10-11 | Xbiotech, Inc. | Interleukin-1α antibodies |
| AU2009291536B2 (en) | 2008-09-12 | 2012-08-16 | Xbiotech Inc. | Targeting pathogenic monocytes |
| US8697689B2 (en) | 2008-10-16 | 2014-04-15 | Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
| SG172855A1 (en) | 2009-01-29 | 2011-08-29 | Abbott Lab | Il-1 binding proteins |
| FR2945396A1 (fr) * | 2009-05-07 | 2010-11-12 | St Microelectronics Grenoble 2 | Procede et dispositif d'analyse de la propagation de transactions dans un reseau multi-protocoles d'un systeme sur puce |
| AR078650A1 (es) | 2009-10-15 | 2011-11-23 | Abbott Lab | Anticuerpo de union a il-1 beta |
| LT2575884T (lt) | 2010-06-03 | 2018-09-25 | Abbvie Biotechnology Ltd | Panaudojimai ir kompozicijos, skirti pūlingo hidradenito (hs) gydymui |
| WO2011159976A2 (en) | 2010-06-18 | 2011-12-22 | Xbiotech, Inc. | Arthritis treatment |
| CN103153340A (zh) | 2010-08-23 | 2013-06-12 | 埃克斯生物科技公司 | 对肿瘤疾病的治疗 |
| CN103328511B (zh) | 2010-09-10 | 2016-01-20 | 埃派斯进有限公司 | 抗-IL-1β抗体及其使用方法 |
| US20120275996A1 (en) | 2010-12-21 | 2012-11-01 | Abbott Laboratories | IL-1 Binding Proteins |
| US9724409B2 (en) | 2011-04-01 | 2017-08-08 | Xbiotech, Inc. | Treatment of inflammatory skin disease |
| DK2694107T3 (en) | 2011-04-01 | 2018-12-10 | Xbiotech Inc | TREATMENT OF DERMATOLOGICAL DISORDERS |
| JP5812669B2 (ja) | 2011-04-27 | 2015-11-17 | キヤノン株式会社 | 画像処理装置および画像処理方法およびコンピュータプログラム。 |
| ES2695102T3 (es) | 2011-09-23 | 2019-01-02 | Xbiotech Inc | Tratamiento para la caquexia |
| US20130195877A1 (en) | 2012-01-31 | 2013-08-01 | Xbiotech, Inc. | Treatment of cachexia by targeting interleukin-1 beta |
| US9545441B2 (en) | 2012-09-18 | 2017-01-17 | Xbiotech, Inc. | Treatment of diabetes |
| AU2013327501B2 (en) | 2012-10-04 | 2018-08-09 | Xbiotech Inc. | Treating vascular disease and complications thereof |
| KR20150064091A (ko) | 2012-10-04 | 2015-06-10 | 엑스바이오테크, 인크. | 정신의학적 병태의 치료법 |
| JP6371758B2 (ja) | 2013-03-12 | 2018-08-08 | 全薬工業株式会社 | 抗ブドウ球菌抗体、その製造方法並びにその使用 |
| US20150024031A1 (en) | 2013-07-17 | 2015-01-22 | Baxter International Inc. | Methods And Compositions For Reducing Pain, Inflammation, And/Or Immunological Reactions Associated With Parenterally Administering A Primary Therapeutic Agent |
| KR101753553B1 (ko) | 2014-06-03 | 2017-07-03 | 엑스바이오테크, 인크. | 스타필로코커스 아우레우스 감염의 치료 및 예방을 위한 조성물 및 방법 |
| CN110382001A (zh) | 2017-02-16 | 2019-10-25 | 埃克斯生物科技公司 | 化脓性汗腺炎的治疗 |
-
2011
- 2011-08-23 CN CN2011800476614A patent/CN103153340A/zh active Pending
- 2011-08-23 KR KR1020177026757A patent/KR101910760B1/ko active Active
- 2011-08-23 EP EP11820492.4A patent/EP2608808B1/en active Active
- 2011-08-23 KR KR1020217032773A patent/KR20210128021A/ko not_active Ceased
- 2011-08-23 KR KR1020207002089A patent/KR102314003B1/ko active Active
- 2011-08-23 MX MX2016013346A patent/MX388939B/es unknown
- 2011-08-23 JP JP2013526085A patent/JP6241932B2/ja active Active
- 2011-08-23 US US13/215,464 patent/US10294296B2/en active Active
- 2011-08-23 KR KR1020187029749A patent/KR102104296B1/ko active Active
- 2011-08-23 WO PCT/US2011/048747 patent/WO2012027324A2/en not_active Ceased
- 2011-08-23 KR KR1020137007024A patent/KR20130108305A/ko not_active Ceased
- 2011-08-23 KR KR1020247029350A patent/KR102748255B1/ko active Active
- 2011-08-23 EP EP16165736.6A patent/EP3075394B1/en active Active
- 2011-08-23 RU RU2013110030/15A patent/RU2013110030A/ru unknown
- 2011-08-23 PT PT118204924T patent/PT2608808T/pt unknown
- 2011-08-23 DK DK11820492.4T patent/DK2608808T3/en active
- 2011-08-23 NZ NZ607472A patent/NZ607472A/en unknown
- 2011-08-23 ES ES18199427T patent/ES2856723T3/es active Active
- 2011-08-23 ES ES11820492.4T patent/ES2622482T3/es active Active
- 2011-08-23 AU AU2011293554A patent/AU2011293554B9/en active Active
- 2011-08-23 EP EP18199427.8A patent/EP3443985B1/en active Active
- 2011-08-23 SG SG2013011242A patent/SG187853A1/en unknown
- 2011-08-23 PH PH1/2013/500316A patent/PH12013500316A1/en unknown
- 2011-08-23 RU RU2017112088A patent/RU2679119C2/ru active
- 2011-08-23 CN CN201710452010.2A patent/CN107252484A/zh active Pending
- 2011-08-23 CN CN201710556357.1A patent/CN107281488B/zh active Active
- 2011-08-23 KR KR1020167013067A patent/KR20160062200A/ko not_active Ceased
- 2011-08-23 MX MX2013002160A patent/MX342776B/es active IP Right Grant
-
2013
- 2013-02-25 ZA ZA2013/01420A patent/ZA201301420B/en unknown
-
2016
- 2016-03-30 PH PH12016500578A patent/PH12016500578B1/en unknown
- 2016-05-19 JP JP2016100753A patent/JP6917681B2/ja active Active
-
2018
- 2018-11-07 IL IL262856A patent/IL262856B/en active IP Right Grant
- 2018-12-20 US US16/228,060 patent/US11932688B2/en active Active
-
2019
- 2019-07-05 JP JP2019125907A patent/JP7316120B2/ja active Active
-
2020
- 2020-06-14 IL IL275350A patent/IL275350B/en unknown
-
2021
- 2021-06-09 JP JP2021096528A patent/JP2021138750A/ja active Pending
-
2023
- 2023-08-11 US US18/448,526 patent/US20230382989A1/en active Pending
-
2025
- 2025-08-08 JP JP2025133305A patent/JP2025166117A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017112088A (ru) | Лечение неопластических заболеваний | |
| RU2018105655A (ru) | Комбинированная терапия с применением липосомального иринотекана и ингибитора parp для лечения рака | |
| RU2016112608A (ru) | Лечение рака комбинацией плинабулина и таксана | |
| Caimi et al. | Clinical approach to diffuse large B cell lymphoma | |
| RU2019114963A (ru) | Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo | |
| WO2016051398A8 (en) | Patient-specific immunotherapy for treating heterogeneous tumors | |
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| RU2012156903A (ru) | Способы комбинированной терапии для лечения пролиферативных заболеваний | |
| RU2012153963A (ru) | Лечение рака груди с помощью соединения 4-иод-3-нитробензамид в комбинации с противоопухолевыми средствами | |
| RU2015121367A (ru) | Фармацевтическая комбинация, содержащая ингибитор b-raf и ингибитор деацетилазы гистонов, и ее применение при лечении пролиферативных заболеваний | |
| RU2018103064A (ru) | Комбинация ингибитора hdac и анти-pd-l1-антитела для лечения злокачественной опухоли | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| RU2015145997A (ru) | Противоопухолевое лекарственное средство, включающее низкодозированный гидрохлорида иринотекана гидрат | |
| RU2016112421A (ru) | Протиоопухолевое средство и усилитель противоопухолевого эффекта | |
| JP2013536236A5 (ru) | ||
| EA201792294A1 (ru) | Комбинированное лечение (варианты) с применением серибантумаба | |
| JP2013544892A5 (ru) | ||
| JP2015507020A5 (ru) | ||
| JP2013528215A5 (ru) | ||
| EA201171360A1 (ru) | Противоопухолевая комбинация, содержащая кабазитаксель и капецитабин | |
| RU2015139515A (ru) | Комбинированное лечение | |
| JP2020535180A5 (ru) | ||
| EA201501095A1 (ru) | Эффективное лечение нмрл и прогностический клинический маркер чувствительной к лечению опухоли | |
| RU2016143220A (ru) | Противоопухолевое средство, содержащее противоопухолевый комплекс платины, и усилитель противоопухолевого эффекта | |
| RU2016143243A (ru) | Противоопухолевое средство, содержащее таксановое соединение и усилитель противоопухолевого эффекта |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD4A | Correction of name of patent owner | ||
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20210526 |
|
| TK4A | Correction to the publication in the bulletin (patent) |
Free format text: CORRECTION TO CHAPTER -PC4A- IN JOURNAL 15-2021 FOR INID CODE(S) D N |